TVARDI THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
TVARDI THERAPEUTICS, INC. (TVRD) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $20.69 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $20.69M, a 40.77% increase year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $8.83M, a 55.36% decline year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $12.08M, a 18.31% decline year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$71.40M, a 1108.23% decline year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$35.80M, a 180.91% decline from fiscal 2016.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $44.25M.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$91.68M.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$42.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $20.69M 10-Q · filed 2018-05-09 | $29.52M derived: sum of 2 quarters · filed 2018-05-09 | $41.60M derived: sum of 3 quarters · filed 2018-05-09 | -$29.81M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $8.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $20.90M derived: sum of 2 quarters · filed 2018-03-15 | -$50.50M derived: sum of 3 quarters · filed 2018-03-15 | -$35.80M 10-K · filed 2018-03-15 |
| 2017-09-30 | $12.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$59.33M derived: sum of 2 quarters · filed 2017-11-02 | -$44.63M 10-Q · filed 2017-11-02 | -$24.86M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | -$71.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$56.70M 10-Q · filed 2017-08-03 | -$36.93M derived: sum of 3 quarters · filed 2018-05-09 | -$22.15M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $14.70M 10-Q · filed 2018-05-09 | $34.47M derived: sum of 2 quarters · filed 2018-05-09 | $49.25M derived: sum of 3 quarters · filed 2018-05-09 | $56.34M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $19.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $34.55M derived: sum of 2 quarters · filed 2018-03-15 | $41.63M derived: sum of 3 quarters · filed 2018-03-15 | $44.25M 10-K · filed 2018-03-15 |
| 2016-09-30 | $14.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $21.86M derived: sum of 2 quarters · filed 2017-11-02 | $24.48M 10-Q · filed 2017-11-02 | -$67.19M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $7.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $9.70M 10-Q · filed 2017-08-03 | -$81.97M derived: sum of 3 quarters · filed 2018-03-15 | -$81.97M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $2.61M 10-Q · filed 2017-05-04 | -$89.05M derived: sum of 2 quarters · filed 2018-03-15 | -$89.05M derived: sum of 3 quarters · filed 2018-03-15 | -$89.06M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | -$91.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$91.67M derived: sum of 2 quarters · filed 2018-03-15 | -$91.67M derived: sum of 3 quarters · filed 2018-03-15 | -$91.68M 10-K · filed 2018-03-15 |
| 2015-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$7.00K derived: sum of 2 quarters · filed 2016-11-04 | -$13.00K 10-Q · filed 2016-11-04 | -$28.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$12.00K 10-Q · filed 2016-08-04 | -$27.00K derived: sum of 3 quarters · filed 2017-03-10 | -$48.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$6.00K 10-Q · filed 2016-05-05 | -$21.00K derived: sum of 2 quarters · filed 2017-03-10 | -$42.00K derived: sum of 3 quarters · filed 2017-03-10 | |
| 2014-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$36.00K derived: sum of 2 quarters · filed 2017-03-10 | -$42.00K 10-K · filed 2017-03-10 | |
| 2014-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$27.00K 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | -$6.00K 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$5.00K 10-K · filed 2016-03-11 | ||
| 2013-09-30 | -$4.00K 10-Q · filed 2014-11-10 | |||
| 2012-12-31 | $511.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |